Location History:
- Laytonsville, MD (US) (2006 - 2008)
- Laytsonville, MD (US) (2009)
Company Filing History:
2 out of 2,664 
2 out of 2,198 
1 out of 541 
Years Active: 2006-2009
Title: Kelly Carles-Kinch: Innovator in Antibody Development
Introduction
Kelly Carles-Kinch is a notable inventor based in Laytonsville, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 3 patents to his name, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Among his latest patents is the invention of EphA4 antibodies, which provides agonistic anti-EphA4 antibodies. This invention aims to enhance therapeutic strategies targeting metastatic cells while minimizing damage to normal tissues. Another significant patent is for EphA2 monoclonal antibodies and methods of making and using them. This invention includes a monoclonal antibody that binds to the extracellular domain of an EphA2 receptor molecule, which is crucial in altering the activity of the EphA2 receptor present in cancer cells. The monoclonal antibodies developed by Carles-Kinch are designed to selectively block the growth and invasiveness of metastatic cells, offering promising therapeutic strategies.
Career Highlights
Kelly Carles-Kinch has worked with reputable organizations such as the Purdue Research Foundation and SmithKline Beecham Corporation. His experience in these institutions has contributed to his expertise in antibody development and cancer research.
Collaborations
Throughout his career, Carles-Kinch has collaborated with notable individuals, including Michael Scott Kinch and Katherine E Kilpatrick. These collaborations have further enriched his research and innovations in the field.
Conclusion
Kelly Carles-Kinch is a distinguished inventor whose work in antibody development has the potential to revolutionize cancer treatment. His innovative patents and collaborations highlight his commitment to advancing medical science.